Enfer Medical is delighted to announce that it has acquired the majority shareholding of ELDA biotech. ELDA biotech has a strong history of being a dynamic, innovative provider of sequencing-based solutions and this strategic acquisition builds on synergies, shared vision, mission, values and provides a strong platform for the delivery of a cutting-edge genomics services in Ireland.
Since this acquisition, Enfer Medical has developed a high quality, rapid and relevant SARS-CoV-2 genome surveillance program and is an ongoing contributor to the HPSC-led National COVID-19 Whole Genome Sequencing Surveillance.
Led by Dr. Elaine Kenny, Enfer Medical will continue to develop pathogen genomics services that will equip healthcare providers with solutions to provide the right care to patients in the right place, and at the right time, allowing earlier patient treatment interventions and more precise investigation of outbreaks.
